Export Compliance Policy -

Equilibar ensures that all shipments are done in accordance with Export Administration Regulations (EAR) and any diversion contrary to U.S. Law is prohibited. In order to maintain this compliance, it is essential that Equilibar know the following information regarding your order. If you are not comfortable releasing this information, Equilibar is willing to sign a Non-Disclosure agreement with your company upon request.

Is this product going to be resold?*
- Yes
- No
Is this product going to be exported outside of the United States?*
- Yes
- No
Will this product be used on its own or incorporated into a new product?*
- Used on its own
- Used to create new product
Who is the end user of this product?
Where is the end user of this product located?
What is the end use of this product?*
Company*
In agreement with Equilibar’s Export Compliance Policy and the United States Government, my company agrees to not sell to and/or send Equilibar products to any countries on the US Denied Parties List which includes but is not limited to the US Embargo List and Sanctioned Countries. By checking the box below, I agree that the information provided above is accurate to the best of my ability and agree to work with Equilibar to follow US Export Compliance Laws and Regulations.*
- Agree
If you are unsure if your customer is on the Denied Parties List, please feel free to contact Equilibar and we will be happy to check.
Quote Number
Company*
Name*
Prénom Nom
Date*
MM slash JJ slash AAAA

Journal article focuses on oligonucleotide production using pressure control with built in dampener

Oligonucleotide drugs are made up of short sections of genetic sequences and are used to target disorders in the genetic code. The first drug of this type was used in 1998 during the AIDS epidemic. Since then, the field has accelerated rapidly and today many oligonucleotide drugs are in clinical trials, promising improvements in treatment Read More